{
  "docId": "019de073-cc15-73cb-b985-dc28972c4284",
  "docSlug": "df7f4367d54f16f4cdacd02ff486e30b",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 25,
  "pageCount": 31,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide highlights clinical safety and pharmacokinetic success for an oral formulation of amikacin.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/25",
  "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284",
  "deckJsonHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284.json",
  "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.18,
        "x": 0.01,
        "y": 0.62
      },
      "kind": "callout",
      "text": "QIDP & ODD potentially provide 12+ years exclusivity upon approval\nAccelerated with $4.5M Cystic Fibrosis Foundation award",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "603fb4b9-a40b-49a4-ae48-111f756fbb7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.14,
        "x": 0.02,
        "y": 0.185
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af04b17b-8d6f-4153-b115-f4bcd4265938",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.82,
        "x": 0.15,
        "y": 0.21
      },
      "kind": "list",
      "text": "NTM organisms are a frequent cause of challenging pulmonary infections, especially in patients with pre-existing inflammatory lung diseases such as cystic fibrosis\nLNC formulation enables oral administration, bioavailability and potentially eliminates oto-& nephron-toxicity, both of which are significant risks with the current standard of care, IV amikacin",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c93d1fda-26d3-47ba-a4a0-fcca9414f9c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.77,
        "x": 0.21,
        "y": 0.57
      },
      "kind": "list",
      "text": "Results confirmed earlier findings with legacy formulation at the same doses (200, 400, 800) with an additional higher dose (1000 mg; fasted/fed) tested in this study\nNo SAEs or study discontinuations (only dose-related adverse event was diarrhea (mild to moderate))\nNo evidence of ototoxicity or renal toxicity\nRapid absorption with oral administration (Tmax 2 hours)\nDose-proportional increases in exposure\nExposure significantly lower compared with IV administered amikacin, expected to translate to better safety profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df486fa4-07ef-461e-9faf-8f4de228301e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "MAT2501: NTM Program Overview and SAD Topline Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e705273-dca4-45b3-afb8-0eed4d42b53b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 1,
        "x": 0,
        "y": 0.48
      },
      "kind": "title",
      "text": "Single Ascending Dose (SAD) PK Study Topline Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bde557bc-9207-4a0c-8b2c-3eb49b4f6450",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}